Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Frederick L Ruberg

Showing results (71-80 of 109) with videos related to

Pageof 11
Sort By:
Biorxiv : the Preprint Server for Biology|April 1, 2024
Abnormal global longitudinal strain and reduced serum inflammatory markers in cardiac AL amyloidosis patients without significant amyloid fibril depositionCamille V Edwards, Grace M Ferri, Josue Villegas-Galaviz, et al.
Circulation|July 28, 2010
Testing of low-risk patients presenting to the emergency department with chest pain: a scientific statement from the American Heart AssociationEzra A Amsterdam, J Douglas Kirk, David A Bluemke, et al.
JACC. Cardiovascular Imaging|September 12, 2025
Changes in Myocardial Light Chain Amyloid Burden After Plasma Cell TherapyDominik C Benz, Olivier F Clerc, Sarah A M Cuddy, et al.
Medrxiv : the Preprint Server for Health Sciences|September 25, 2023
Prognostic Value of Left Ventricular <sup>18</sup> F-Florbetapir Uptake in Systemic Light-Chain AmyloidosisOlivier F Clerc, Yesh Datar, Sarah Am Cuddy, et al.
Journal of the American Heart Association|July 24, 2023
Clinical Penetrance of the Transthyretin V122I Variant in Older Black Patients With Heart Failure: The SCAN-MP (Screening for Cardiac Amyloidosis With Nuclear Imaging in Minority Populations) StudyAvni Madhani, Natalia Sabogal, Daniel Massillon, et al.
JACC. Cardiovascular Imaging|December 19, 2021
Myocardial Composition in Light-Chain Cardiac Amyloidosis More Than 1 Year After Successful TherapySarah A M Cuddy, Michael Jerosch-Herold, Rodney H Falk, et al.
JACC. Cardiovascular Imaging|July 13, 2024
Prognostic Value of Left Ventricular <sup>18</sup>F-Florbetapir Uptake in Systemic Light-Chain AmyloidosisOlivier F Clerc, Yesh Datar, Sarah A M Cuddy, et al.
American Journal of Hematology|June 22, 2022
Predictors of hematologic response and survival with stem cell transplantation in AL amyloidosis: A 25-year longitudinal studyJoshua N Gustine, Andrew Staron, Raphael E Szalat, et al.
Journal of Nuclear Cardiology : Official Publication of the American Society of Nuclear Cardiology|February 24, 2023
Diagnostic performance characteristics of planar quantitative and semi-quantitative parameters of Tc<sup>99m</sup> pyrophosphate (PYP) imaging for diagnosis of transthyretin (ATTR) cardiac amyloidosis: the SCAN-MP studyShivda Pandey, Sergio Teruya, Carlos Rodriguez, et al.
Journal of Cardiac Failure|July 14, 2025
Health Literacy and Physical Function Among Older Black and Hispanic Individuals With Heart FailureShabatun J Islam, Sergio Teruya, Denise Fine, et al.
Pageof 11

Showing results (71-80 of 109) with videos related to

Sort By:
Pageof 11
Biorxiv : the Preprint Server for Biology|April 1, 2024
Abnormal global longitudinal strain and reduced serum inflammatory markers in cardiac AL amyloidosis patients without significant amyloid fibril depositionCamille V Edwards, Grace M Ferri, Josue Villegas-Galaviz, et al.
Circulation|July 28, 2010
Testing of low-risk patients presenting to the emergency department with chest pain: a scientific statement from the American Heart AssociationEzra A Amsterdam, J Douglas Kirk, David A Bluemke, et al.
JACC. Cardiovascular Imaging|September 12, 2025
Changes in Myocardial Light Chain Amyloid Burden After Plasma Cell TherapyDominik C Benz, Olivier F Clerc, Sarah A M Cuddy, et al.
Medrxiv : the Preprint Server for Health Sciences|September 25, 2023
Prognostic Value of Left Ventricular <sup>18</sup> F-Florbetapir Uptake in Systemic Light-Chain AmyloidosisOlivier F Clerc, Yesh Datar, Sarah Am Cuddy, et al.
Journal of the American Heart Association|July 24, 2023
Clinical Penetrance of the Transthyretin V122I Variant in Older Black Patients With Heart Failure: The SCAN-MP (Screening for Cardiac Amyloidosis With Nuclear Imaging in Minority Populations) StudyAvni Madhani, Natalia Sabogal, Daniel Massillon, et al.
JACC. Cardiovascular Imaging|December 19, 2021
Myocardial Composition in Light-Chain Cardiac Amyloidosis More Than 1 Year After Successful TherapySarah A M Cuddy, Michael Jerosch-Herold, Rodney H Falk, et al.
JACC. Cardiovascular Imaging|July 13, 2024
Prognostic Value of Left Ventricular <sup>18</sup>F-Florbetapir Uptake in Systemic Light-Chain AmyloidosisOlivier F Clerc, Yesh Datar, Sarah A M Cuddy, et al.
American Journal of Hematology|June 22, 2022
Predictors of hematologic response and survival with stem cell transplantation in AL amyloidosis: A 25-year longitudinal studyJoshua N Gustine, Andrew Staron, Raphael E Szalat, et al.
Journal of Nuclear Cardiology : Official Publication of the American Society of Nuclear Cardiology|February 24, 2023
Diagnostic performance characteristics of planar quantitative and semi-quantitative parameters of Tc<sup>99m</sup> pyrophosphate (PYP) imaging for diagnosis of transthyretin (ATTR) cardiac amyloidosis: the SCAN-MP studyShivda Pandey, Sergio Teruya, Carlos Rodriguez, et al.
Journal of Cardiac Failure|July 14, 2025
Health Literacy and Physical Function Among Older Black and Hispanic Individuals With Heart FailureShabatun J Islam, Sergio Teruya, Denise Fine, et al.
Pageof 11